Marmo v. IBP, Inc.

360 F. Supp. 2d 1019, 2005 U.S. Dist. LEXIS 4475, 2005 WL 638316
District Court, D. Nebraska·Decided January 26, 2005·No. 8:00CV527, 8:00CV529, 8:00CV530, 8:00CV531, 8:00CV532, 8:00CV533, 8:00CV534, 8:00CV535, 8:00CV536, 8:00CV537, 8:01CV27, 8:01CV28, 8:02CV293·Published·Cited by 1 cases

Opinion

MEMORANDUM AND ORDER

CAMP, District Judge.

This matter is before the Court in these consolidated cases on the Defendant’s Motion in Limine (See, e.g., Filing No. 270) regarding Plaintiffs’ designated expert witness Harriet Ammann, Ph.D. The Defendant, IBP, Inc., has submitted briefs (See, e.g., Filing Nos. 284, 331) and index of evidence.(See, e.g., Filing No. 286) in support of its motion, and the Plaintiffs have submitted a brief (See, e.g., Filing No. 310) *1020 and index of evidence (See, e.g., Filing No. 317 A and B) in opposition. On January 24, 2005, the Court received further evidence, including the testimony of Dr. Am-mann, at a hearing on the Defendant’s motion. For the reasons stated below, Dr. Ammann will be permitted to testify in the Plaintiffs’ cases-in-chief regarding the nature and effects of hydrogen sulfide gas, and she will be permitted to offer her opinion that the symptoms reported by the Plaintiffs are “consistent with” or “in keeping with” exposure to such gas. She will not be permitted to offer an opinion that any of the Plaintiffs’ symptoms or injuries were “caused by” exposure to such gas to any degree of probability or certainty. Dr. Ammann will not be permitted to offer testimony in the Plaintiffs’ cases-in-chief based on the reports of the Plaintiffs’ designated rebuttal witnesses who were not listed among Dr. Ammann’s references in her initial expert opinion disclosure.

BACKGROUND

The record in this matter is extensive and the briefing has been thorough. Because the first trial of these cases is imminent and the parties are awaiting the Court’s ruling, this order will address the issues and the Court’s findings in a summary fashion.

Dr. Harriet Ammann is a board-certified toxicologist employed by the State of Washington Department of Ecology Air Quality Program. She has substantial expertise in the nature and effects of poisons, including hydrogen sulfide gas. (Ex. 1, Ammann Curriculum Vitae). Dr. Ammann has studied reports of hydrogen sulfide air concentrations in the region of Dakota City and South Sioux City, Nebraska, for relevant times, issued by the Nebraska Department of Environmental Quality (“NDEQ”), the Agency for Toxic Substances and Disease Registry (“ATSDR”), and individual witnesses’ reports based on private monitoring of hydrogen sulfide gas levels. (Abstract of Opinion, Filing No. 317B, Attachment 2A, “First Ammann Report”). She has also studied meteorological and air-modeling data for the region for relevant times. (Supplement to Expert Report, Filing No. 317B, Attachment 2B, “Second Ammann Report”). She interviewed 17 individual Plaintiffs for about 15 minutes each regarding their symptoms, and she has drawn temporal connections between their reports of symptoms and their exposure to hydrogen sulfide emissions. (First Ammann Report p. 35, and Transcript from January 24, 2005, Hearing at 62:3-17, hereafter “Ammann Testimony.”). Dr. Ammann also reviewed certain medical records of the Plaintiffs to look for pre-existing conditions and sensitivities. (Second Ammann Report p. 10; Amman Testimony at 42:7 — 12). 1 Based on her expertise in the nature and effects of hydrogen sulfide gas, her review of reports showing levels of hydrogen sulfide emissions in the subject area, her interviews of 17 Plaintiffs, and her review of certain medical records, Dr. Ammann offered her opinion that the symptoms reported by the Plaintiffs were “in keeping with” exposure to hydrogen sulfide gas, and that the symptoms were “more likely than not” attributable to such exposure. (First Am-mann Report p. 21).

Dr. Ammann is not a medical doctor, has not examined any of the Plaintiffs, and has not conducted any differential diagnosis to rule out any other potential causes of the *1021 Plaintiffs’ symptoms. (Filing No. 286, Ex. 1, Deposition of Dr. Ammann, Oct. 22, 2002 (“Ammann Depo.”) 96:2-24; Ammann Testimony at 76:8, 78:10-12). Although in her deposition Dr. Ammann testified that she could not draw a causal link between the Plaintiffs’ exposure to hydrogen sulfide gas and their injuries (Amman Depo. 96:21-24), at the time of the hearing on this matter Dr. Ammann testified that the Plaintiffs’ symptoms and alleged injuries were caused by exposure to hydrogen sulfide gas “by a reasonable degree of scientific certainty.” (Ammann Testimony at 46:3-6). She testified that she understood the term “reasonable degree of scientific certainty” to mean “more probable than not,” although not subject to expression in terms of a potential for error, and that it was a much lower standard than “scientific causation.” 2

ANALYSIS

This Court must determine whether Dr. Ammann’s specialized knowledge will assist the trier of fact to understand evidence or to determine a fact in issue. (Fed. R. Ev.702). Under Rule 702, the Court must consider whether (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.

In determining the reliability of a scientist’s methodology, the Court should consider whether a theory or technique can be and has been tested, whether it has been subject to peer review or publication, whether it has known or potential error rates or standards and controls, and whether it has gained general acceptance in the scientific community. Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593-94, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993); Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 141, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999). Dr. Am-mann’s methodology for her opinion that the Plaintiffs’ symptoms and injuries were caused by hydrogen sulfide emissions does not meet these Daubert and Kumho standards.

The Advisory Committee Notes to the 2000 Amendments to Rule 702, made in response to the Daubert decision, list other factors courts often consider when determining whether expert testimony is sufficiently reliable to be considered by the trier of fact. Among these are (1) whether the research was conducted independent of the litigation or the opinions were developed expressly for purposes of the litigation, (2) whether the expert has extrapolated from an accepted practice to an unfounded conclusion, leaving an analytical gap, (3) whether the expert has adequately accounted for alternative explanations, at a minimum ruling out the most obvious alternative causes, (4) whether the expert has employed the same level of care and intellectual rigor in reaching the opinion as the expert would employ when working outside the courtroom in the expert’s field of expertise, and (5) whether the field of expertise claimed by the expert is known to reach reliable results for the type of opinion the expert is offering.

*1022 With respect to Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Marmo v. IBP, Inc., 360 F. Supp. 2d 1019, 2005 U.S. Dist. LEXIS 4475, 2005 WL 638316 (D. Neb. 2005).

360 F. Supp. 2d 1019 (Marmo v. IBP, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Grant v. PHARMATIVE, LLC
452 F. Supp. 2d 903 (D. Nebraska, 2006)